Dergiler / Annals of Medical Research / 2019 / Cilt: 26 - Sayı: 9

The association of fibroblast growth factor 23 with atherosclerosis and arterial stiffness in peritoneal dialysis patients

Sayfa
2060–2067
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

There wasno relationship between FGF-23 and atherosclerosis and arterial stiffness in PD patients.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: Increased serum fibroblast growth factor-23 (FGF-23) levels are associated with adverse cardiovascular events in chronickidney disease patients.
📊
Temel Bulgular & Veri:The aim of our study was to investigate the association of FGF-23 with atherosclerosis and arterial stiffnessin patients with peritoneal dialysis (PD).Material and Methods: This cross-sectional study was performed in 55 (34 (61.8%) male/21 (38.2%) female) PD patients with amean age of 53.1±11.4 years.
💡
Sonuç & Katkı:There wasno relationship between FGF-23 and atherosclerosis and arterial stiffness in PD patients.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Aim: Increased serum fibroblast growth factor-23 (FGF-23) levels are associated with adverse cardiovascular events in chronickidney disease patients. The aim of our study was to investigate the association of FGF-23 with atherosclerosis and arterial stiffnessin patients with peritoneal dialysis (PD).Material and Methods: This cross-sectional study was performed in 55 (34 (61.8%) male/21 (38.2%) female) PD patients with amean age of 53.1±11.4 years. The presence of atherosclerosis was determined by carotid artery-intima media thickness (CA-IMT)and the presence of arterial stiffness was determined by brachial-ankle pulse wave velocity (baPWV). Residual renal function wasdetermined by residual glomerular filtration rate (rGFR), renal creatinine clearance (CCr), and residual urine output. FGF-23 andsoluble klotho (s-KL) levels were determined by enzyme-linked immunosorbent assay.Results: CA-IMT (p 2.16. In multiple regression analysis there was an inverse relationship between log10 FGF-23 and rGFR (p =0.032), residual diuresis (p = 0.048), renal CCr (p = 0.045). There was no relationship with log10 FGF-23 and CA-IMT, baPWV (p > 0.05).Conclusion: Increased atherosclerosis and arterial stiffness were detected in PD patients compared to healthy subjects. There wasno relationship between FGF-23 and atherosclerosis and arterial stiffness in PD patients.

🔖

Bu Makaleye Atıf Yap

DOLU, S., ASİLTÜRK, E., SOZER, Y. K., COBAN, M., EROL, B., ELLİDAG, H. Y., İNCİ, A. (2022). The association of fibroblast growth factor 23 with atherosclerosis and arterial stiffness in peritoneal dialysis patients. Annals of Medical Research, Cilt: 26 - Sayı: 9, 2060–2067. https://ajindex.com/articles/447172

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Prichard S. Major and minor risk factors for cardiovascular disease in peritoneal dialysis. Perit Dial Int 2000;20 S154-9
  2. Attman PO, Samuelsson OG, Moberly J, et al. ApolipoproteinB-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int 1999;55:1536-42
  3. Gao N, Kwan BC, Chow KM, et al. Arterial pulse wave velocity and peritoneal transport characteristics independently predict hospitalization in Chinese peritoneal dialysis patients. Perit Dial Int 2010;30:80-5
  4. Covic A, Goldsmith DJ, Florea L, et al. The influence of dialytic modality on arterial stiffness, pulse wave reflections, and vasomotor function. Perit Dial Int 2004;24:365-72
  5. Szeto CC, Kwan BC, Chow KM, et al. Prognostic value of arterial pulse wave velocity in peritoneal dialysis patients. Am J Nephrol 2012;35:127-33
  6. Jung JY, Hwang YH, Lee SW, et al. Factors associated with aortic stiffness and its change over time in peritoneal dialysis patients. Nephrol Dial Transplant 2010;25:4041-8
  7. Fukagawa M, Kazama JJ. With or without the kidney: the role of FGF23 in CKD. Nephrology Dialysis Transplantation 2005;20:1295–1298
  8. Adragao T, Pires A, Lucas C, et al. A simple vascular calcification score predicts cardiovascular risk in hemodialysis patients. Nephrol Dial Transplant 2004;19:1480-8
  9. Balci M, Kirkpantur A, Gulbay M, et al. Plasma fibroblast growth factor-23 levels are independently associated with carotid arteryatherosclerosis in maintenance hemodialysis patients. Hemodial Int 2010;14:425-32
  10. Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004;113:561-8
  11. Inaba M, Okuno S, Imanishi Y, et al. Role of fibroblast growth factor-23 in peripheral vascular calcification in nondiabetic and diabetic hemodialysis patients. Osteoporos Int 2006;17:1506-13
  12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
  13. Canada-USA (CANUSA) peritoneal dialysis study group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. J Am Soc Nephrol 1996;7:198-207
  14. Van-Olden RW, Krediet RT, Struijk DG, et al. Measurement of residual renal function in patients treated with continuous peritoneal dialysis. J Am Soc Nephrol 1996;7:745-50.